Avastin fails only Phase III trial in advanced prostate cancer
12 March 2010
Malini Guha
Roche's Avastin (bevacizumab), the world's best-selling cancer drug, has failed to prolong overall survival in its only Phase III trial in advanced prostate cancer, CALGB 90401, which was sponsored by the US National Cancer Institute (NCI).
Roche said it was analysing the data to determine the...
Please Login to read the full article.
12 March 2010
Malini Guha
Roche said it was analysing the data to determine the...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Adverse effects cast doubt over Sanofi's Taxotere follow on Jevtana, says NICE
- Nexavar enters Phase III for breast cancer
- Sanofi turns to G-BA for Jevtana benefits decision after vague IQWiG's assessment
- SMC vetoes Sanofi's Jevtana, AZ's Vimovo and Merck's Emend, but OKs Simponi again
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
